Invesco Biotechnology & Genome ETF Rating → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free PBE Stock Alerts $63.75 -0.40 (-0.62%) (As of 05/8/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy2.70Holdings in PBE have an aggregate rating of Moderate Buy based on 338 analyst ratings issued in the past year covering 29 companies (97.2% of the portfolio).PBE Aggregate Price Target$84.3532.32% UpsideHigh Prediction$110.34Average Prediction$84.35Low Prediction$60.68Holdings in PBE have an aggregate price target of $84.35 and a range of $60.68 to $110.34 covering 29 companies (97.2% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy6 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 29 PBE Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.55%NBIXNeurocrine Biosciences$139.02-2.9%5 of 5 stars2.74$147.88 6.4%23Analyst Revision5.08%AMGNAmgen$307.31+2.3%5 of 5 stars2.52$305.05 -0.7%21Earnings ReportAnalyst Revision5.05%VRTXVertex Pharmaceuticals$418.82+2.1%4 of 5 stars2.48$432.18 3.2%25Earnings ReportAnalyst Forecast5.03%REGNRegeneron Pharmaceuticals$955.76-1.5%4 of 5 stars2.70$981.71 2.7%204.95%BMRNBioMarin Pharmaceutical$81.83-0.9%5 of 5 stars2.63$107.50 31.4%19Insider Selling4.93%BIIBBiogen$219.72+0.4%5 of 5 stars2.65$290.92 32.4%26Positive News4.84%GILDGilead Sciences$64.92-0.8%5 of 5 stars2.39$83.69 28.9%184.76%TECHBio-Techne$77.05-0.5%4 of 5 stars2.82$80.50 4.5%11Earnings ReportDividend Announcement3.38%MNKDMannKind$4.40-1.6%2 of 5 stars3.00$8.00 81.8%3Earnings ReportUpcoming EarningsNews Coverage3.32%EXELExelixis$21.59-2.5%5 of 5 stars2.63$26.33 22.0%16Analyst Revision3.26%COLLCollegium Pharmaceutical$38.06+2.0%2 of 5 stars2.60$39.00 2.5%5Upcoming EarningsNews Coverage3.21%UTHRUnited Therapeutics$261.09-1.9%5 of 5 stars2.90$308.78 18.3%10Earnings ReportInsider Selling3.11%HALOHalozyme Therapeutics$42.01+1.9%5 of 5 stars2.86$53.29 26.8%7Analyst ForecastNews Coverage3.10%CPRXCatalyst Pharmaceuticals$14.72-2.8%5 of 5 stars3.00$26.43 79.5%5News Coverage3.06%TGTXTG Therapeutics$17.12-0.3%4 of 5 stars2.83$29.83 74.3%6Earnings ReportAnalyst Revision2.90%BPMCBlueprint Medicines$108.78+0.2%1 of 5 stars2.50$100.31 -7.8%16Analyst ForecastInsider SellingAnalyst RevisionNews Coverage2.86%PTCTPTC Therapeutics$31.14-2.0%2 of 5 stars1.92$33.67 8.1%13Gap Down2.85%ITCIIntra-Cellular Therapies$67.00-5.9%5 of 5 stars2.90$90.17 34.6%10Earnings ReportAnalyst ForecastNews Coverage2.75%IONSIonis Pharmaceuticals$40.16-1.9%4 of 5 stars2.71$59.54 48.3%14Earnings ReportAnalyst ForecastInsider SellingNews CoveragePositive News2.74%CLDXCelldex Therapeutics$41.21-2.4%1 of 5 stars2.80$66.00 60.2%5Analyst ForecastNews Coverage2.68%VCELVericel$47.69-3.7%1 of 5 stars3.00$46.40 -2.7%6News CoverageGap Down2.65%DVAXDynavax Technologies$11.65-0.9%4 of 5 stars2.75$25.00 114.6%4News Coverage2.42%RGENRepligen$165.50-1.3%4 of 5 stars2.89$197.75 19.5%9Earnings ReportAnalyst Revision2.41%XENEXenon Pharmaceuticals$42.93-1.2%3 of 5 stars3.00$59.44 38.5%9Upcoming EarningsNews CoveragePositive News2.27%VCYTVeracyte$20.12-4.3%4 of 5 stars2.60$27.50 36.7%5Earnings ReportAnalyst ForecastNews CoverageGap Up2.23%MYGNMyriad Genetics$23.95+21.1%2 of 5 stars2.33$23.17 -3.3%7Earnings ReportAnalyst UpgradeNews CoverageGap UpHigh Trading Volume2.16%FOLDAmicus Therapeutics$10.14-2.7%4 of 5 stars3.00$20.00 97.2%3Upcoming EarningsNews Coverage1.91%ACADACADIA Pharmaceuticals$17.13-0.7%4 of 5 stars2.80$31.75 85.3%15Analyst Forecast1.70%EYPTEyePoint Pharmaceuticals$11.56-2.6%2 of 5 stars3.00$34.14 195.4%7Analyst ForecastInsider BuyingNews Coverage This page (NYSEARCA:PBE) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarningsWatch this FREE trading tutorial while it’s still availableInvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
